FibroGen Prices $326M Follow-On To Fund Cancer Drug
Anemia treatment developer FibroGen has raised $326 million in a follow-on stock offering advised by Cooley LLP and Perkins Coie LLP, generating money that will fund additional product development including a...To view the full article, register now.
Already a subscriber? Click here to view full article